Miozac Solution for Intravenous Infusion
Dobutamine
250 mg/20 ml
FISIOPHARMA SRL
| Pack size | 1 Glass vial (20 ml) |
|---|---|
| Dispensing mode | POM |
| Source | ITALY |
| Agent | TRANS ARABIA DRUG STORE |
| Retail Price | 37.50 AED |
Indications
Miozac Solution for Intravenous Infusion is used for:
Heart failure, Cardiac stress test
Adult Dose
Cardiac Decompensation
0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min
Adjust according to patient's BP, heart rate, cardiac and urine output.
Child Dose
Cardiac Decompensation
0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min
Renal Dose
Administration
IV Preparation
Solution: Dilute 250 mg in 250 mL of compatible solution to yield final concentration of 1000 mcg/mL; not to exceed 5000 mcg/mL
The rate of administration and the duration of therapy should be adjusted according to the patient's response, The indicators are: haemodynamic parameters such as heart rate and rhythm, arterial pressure, and, whenever possible, cardiac output and measurements of ventricular filling pressures and signs of pulmonary congestion.
Because of its short half-life, Dobutamine Hydrochloride must be administered as a continuous intravenous infusion. Following the initiation of a constant rate infusion, or upon changing the rate, a steady-state dobutamine plasma concentration is achieved within approximately 10 minutes. Thus, loading doses or bolus injections are not necessary and are not recommended.
Contra Indications
Hypersensitivity; idiopathic hypertrophic subaortic stenosis (IHSS).
Precautions
Correct hypovolaemia prior to treatment. Increased risk of rapid ventricular response in patients with atrial fibrillation. Insufficient data to determine the safety and efficacy of dobutamine use after acute MI. Elderly. Neonates. Pregnancy.
Lactation: Unknown whether drug is excreted into breast milk; avoid use
Pregnancy-Lactation
Pregnancy category: B
Lactation: Unknown whether drug is excreted into breast milk; avoid use
Interactions
Increased cardiac output when used with nitroprusside. Increased vasopressor effect of dobutamine when used with bretylium, guanethidine, oxytocic drugs or TCAs.
Adverse Effects
Side effects of Dobutamine :
1-10%
Tachyarrhythmia (10%), Hypertension (7.5%), Eosinophilic myocarditis (<7%), Premature ventricular beats (5%; dose related), Angina (1-3%), Dyspnea (1-3%), Fever (1-3%), Headache (1-3%), Nausea (1-3%), Palpation (1-3%)
Frequency Not Defined
Cardiac dysrhythmia, Exacerbation of coronary arteriosclerosis, Hypokalemia, Injection-site reactions, Syncope, 10- to 20-mm Hg increase in systolic blood pressure and increase in heart rate of 5 to 15 beats/min
Potentially Fatal: Cardiac arrhythmias, allergy (rare), MI and hypotension.
Mechanism of Action
Dobutamine increases contractility and heart rate by stimulating ?-adrenergic receptors in the cardiac tissues.
Note
Miozac 250 mg/20 ml Solution for Intravenous Infusion manufactured by FISIOPHARMA SRL. Its generic name is Dobutamine. Miozac is availble in United Arab Emirates.
Farmaco UAE drug index information on Miozac Solution for Intravenous Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.